RIVERSIDE, Calif., April 7, 2026 /PRNewswire/ — PartnerOne, one of the fastest-growing software groups in the world, has appointed Michael Detwiler as the new Chief Executive Officer for Mortgage Cadence.

PartnerOne recently acquired Mortgage Cadence, a leading provider of cloud-based digital lending solutions.

Mike is the original CEO and co-founder of Mortgage Cadence, building it into a leader in the mortgage industry. He is a very well-respected leader and a visionary executive with over 30 years of experience in mortgage lending software. After having grown Mortgage Cadence from its first steps in [2002] to 2015, Mike is back to lead it into the next decades of growth and innovation. He brings a strong record of scaling organizations, driving investments, and aligning people and technology to deliver a culture of customer centric success.

“I couldn’t be more enthusiastic about leading Mortgage Cadence as part of PartnerOne,” said Detwiler. “Our customers can plan on continued innovation in the age of AI and more importantly their being central to everything we do every day.”

“We are delighted to welcome Mike as our Mortgage Cadence CEO,” said Suzanne Fortman, Vice President at PartnerOne. “He brings a proven record of high performance and exemplary customer service that aligns seamlessly with PartnerOne’s fast-paced culture and long-term investment strategy. Mike is committed to building upon the company’s strong foundation, empowering teams, and driving sustainable growth as we continue to accelerate our momentum within the PartnerOne portfolio.” 

About PartnerOne 

PartnerOne is one of the fastest growing enterprise software groups in the world, with a proven track record of acquiring and growing enterprise software companies. Over 2000 enterprises and government organizations rely on PartnerOne software, including 80% of the largest companies in the world. With an “Acquire. Invest. Grow.” philosophy, PartnerOne provides a “forever-home” for acquired businesses and helps them thrive with shared resources and sustained investment. For more information, visit www.partnerone.com

About Mortgage Cadence 
Mortgage Cadence delivers the industry’s most complete, modern, cloud-based digital lending platform designed to provide an exceptional user experience throughout the entire mortgage lending life cycle, across all channels and products. With leading borrower point-of-sale through closing collaboration tools, the end-to-end platform is both complete and configurable, offering an open architecture designed to meet the needs of today’s lenders. The platform enables lenders to work more efficiently, leveraging automation and workflow tools that deliver excellent borrower, sales, and operational user experience. For more information, visit www.mortgagecadence.com. 

TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation

CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, April 7, 2026 /PRNewswire/ — TriNetX, the world’s leading federated health data network, today announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX’s genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers’ ability to integrate phenotypic and multiomic data for improved care delivery and clinical research and enhances the ability of TriNetX’s life science customers to perform large-data research in a cost-effective manner. 

Zetta’s flagship platform, XetaBase, is a multiomic capture and analytics platform designed for population‑scale genomic analysis. XetaBase is currently in use by leading healthcare provider organizations, life sciences companies, and research institutes.

TriNetX and Zetta have worked closely together since 2024 as part of TriNetX’s genomics data program. During this collaboration, the companies completed substantial technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data to deliver high-integrity, analytically robust insights. This work establishes a strong foundation for further expansion.

“Through our partnership activities, led by our Chief Operating Officer Steve Kundrot and team, we have developed deep familiarity with Zetta’s leadership, technological prowess, and fit-for-purpose approach and have been consistently impressed with Zetta’s trusted healthcare provider relationships and robust analytics platform,” said Jeff Margolis, Executive Chairman of TriNetX. “Welcoming Zetta’s XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization.”

Mr. Margolis continued, “This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures.”

Jeffrey Brown, PhD, TriNetX Chief Scientific Officer added, “Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology, as we strongly believe the integration of different data types is essential to clinical and scientific progress.” 

“I am proud of what the Zetta team has built and excited to see XetaBase become part of the TriNetX array of data, software, and intelligence capabilities,” said Ignacio Medina Castello, Chief Executive Officer and Chief Technology Officer of Zetta Genomics. “From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale. Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners.”

About TriNetX, LLC

TriNetX is The Global Truth Engine for Better Human Health™, helping organizations understand what’s really happening in patient care. We connect health systems, researchers, and companies around the globe to real‑world patient data so they can make better‑informed decisions—based on reality, not assumptions.

Data is sourced directly from 11,000+ healthcare provider sites across more than 20 countries and kept within those institutions to protect accuracy, privacy, and trust. TriNetX combines this data with scientific expertise and technology to help customers ask better questions, interpret results, and move forward with confidence.

Learn more at trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com

-Fixed–dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-life of up to 12 hours. These data support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for obesity. 

-ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39 when combined together, with room temperature stability and a small pill size.

-ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinal (GI) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration. 

-ASC39, an oral small molecule amylin-selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.

-Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets is expected in the third quarter of 2026.

HONG KONG, April 7, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30, once-daily oral small molecule GLP-1R agonist and ASC39, once-daily oral small molecule amylin-selective amylin receptor agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets for the treatment of obesity in the third quarter of 2026.

ASC30_39 FDC tablets, dosed orally in dogs, demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key parameters of ASC30_39 FDC tablets are consistent with those observed in their respective monotherapies in a head-to-head dog study. Furthermore, ASC30_39 FDC tablets, developed utilizing Ascletis’ proprietary formulation technology, demonstrated a good compatibility between ASC30 and ASC39 with room temperature stability and a small pill size. The combination of the excellent pharmacokinetic profile of ASC30_39 FDC, the potential best- in-class efficacy and gastrointestinal (GI) tolerability of ASC30 and the first eloralintide-like small molecule amylin support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for the treatment of obesity.

ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinal (GI) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration in non-head-to-head studies (Press release).

As a clinical development candidate, ASC39 is a potent and amylin-selective oral small molecule amylin receptor agonist and demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.

“Selection of this fixed dose combination, which we believe is the first publicly announced co-formulation of an oral GLP-1 and an oral amylin, is an important step in the development of a new oral, potentially synergistic combination of ASC30 and ASC39 for the treatment of obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “We believe this fixed dose combination, which combines the key features of high bioavailability, high drug exposure, a long half-life, and the convenience of a small pill, has the opportunity to improve patient outcomes for the treatment of obesity.”

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

TAIPEI, April 7, 2026 /PRNewswire/ — Cathay Financial Holdings (Cathay FHC) today announced a long-term strategic collaboration with OpenAI to strengthen the Group’s core capabilities in AI research, deployment, and governance. Cathay FHC is the first financial institution organization to work with OpenAI at this scale to bring AI advanced capabilities into its operations in Taiwan.

As artificial intelligence reshapes industries worldwide, financial institutions are increasingly exploring how advanced AI can transform internal operations, strengthen decision-making, and enhance customer services.

Under this agreement, Cathay FHC will deploy ChatGPT Enterprise across its subsidiaries and equip its employees with secure, enterprise-grade AI tools that are built with security and regulatory compliance. The roll-out will support teams in their day-to-day work while accelerating the development of new AI powered applications.

“Cathay FHC will leverage OpenAI’s technologies and engineering expertise to progressively introduce Agentic AI into our existing financial workflows. This will deepen intelligent and automated applications across business scenarios and support the transformation of our operating models,” said Marcus Lopez, Chief Technology Officer of Cathay Financial Holdings. “In addition, both parties will develop structured training and enablement programs to strengthen employees’ AI proficiency, enabling AI to become an effective digital teammate that elevates operational performance and modernizes workplace practices.”

“Cathay FHC has a clear vision for bringing advanced AI into the financial sector in a responsible and innovative way. We look forward to working together to roll out ChatGPT Enterprise and build secure, compliant solutions that help their teams move faster and deliver better outcomes for their customers,” said Oliver Jay, Managing Director, International of OpenAI.

A key focus of this collaboration is the creation of an enterprise-grade AI workstation that integrates OpenAI’s advanced large language model capabilities with Cathay FHC’s internal knowledge bases and proprietary intelligent agents. The platform will deliver a scalable, governable intelligent work environment and AI assistants for employees. It will enhance knowledge processing and day-to-day operations such as document summarization and rewriting, data synthesis, presentation generation, and operational inquiries. The workstation will also support natural-language-based code generation to accelerate engineering development and business automation. Secure integration with existing enterprise systems will further streamline workflow connectivity and improve information accessibility.

In addition to deploying ChatGPT Enterprise, Cathay FHC is also using OpenAI’s API to build new AI applications. Two initial initiatives focus on developing agentic AI systems for corporate banking and insurance. OpenAI will extend its technical experts to build an intelligent agent engine capable of multi-agent orchestration, along with a continuously evolving financial-domain knowledge system. These advancements will enhance operational efficiency while strengthening risk management and decision transparency, ensuring that all applications meet rigorous regulatory and compliance requirements.

Looking ahead, Cathay FHC will remain customer-centric and also advance an “AI as a Service” (AIaaS) approach, embedding AI significantly into employee workflows, service processes, and financial products. With a strong foundation of security and resilience, Cathay FHC will continue collaborating with strategic partners to shape a forward-looking, robust blueprint for next-generation digital finance.

VICTORIA, Seychelles, April 7, 2026 /PRNewswire/ — MEXC, the world leader in 0‑fee digital asset trading, has listed two Ondo tokenized stock trading pairs on its spot market, tied to leading quantum computing companies. The move further expands the range of real-world assets (RWA) available to users on the platform.

IONQON/USDT and RGTION/USDT were listed on April 6, 2026, at 12:00 UTC. Withdrawals are enabled from April 7, 2026, at 12:00 UTC.

IONQON and RGTION represent tokenized versions of IonQ and Rigetti Computing, two publicly listed pure-play quantum computing companies at the forefront of a sector gaining increasing commercial momentum. Both tokens are issued through Ondo Global Markets, a platform designed to bring traditional public securities onchain, with tokens that are freely transferable and usable in DeFi.

The listings reflect MEXC’s broader commitment to serving as a bridge between traditional financial markets and the digital asset ecosystem. By integrating tokenized real-world assets into its platform, MEXC enables users to access infinite opportunities across diverse markets within a single interface. Guided by a user-centered approach, MEXC continues to enhance its platform, ensuring users have timely and efficient access to relevant trading solutions as markets evolve.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.

MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

Risk Disclaimer:

This content does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, project fundamentals, and potential financial risks before making any trading decisions.

BEIJING, April 7, 2026 /PRNewswire/ — During a recent industry event in Beijing, China, EVE Energy announced multiple major advances in the energy storage sector. The company officially launched its next-generation 6.9MWh large-format battery energy storage system (BESS), held a certification ceremony for its 628Ah large-format battery system passing a large-scale fire test by an internationally recognized authority, and signed strategic cooperation agreements totaling over 50GWh for its large-format batteries.

6.9MWh System Global Debut: Focus on Efficiency and Safety

The newly launched 6.9MWh BESS, the latest addition to EVE Energy’s Mr.Big Family, is built on the company’s mature battery platform. Housed in a standard 20-foot container, the system achieves a 10% increase in energy density compared to previous generations, with cell-level volumetric energy density exceeding 430Wh/L. Through structural optimization, its footprint is reduced by 6%, saving approximately RMB 2.6 million in initial investment per station. The system delivers 10,000 cycles at 70% state of health (SOH), with temperature differential kept within 5°C using active balancing and precision thermal management. On the safety front, the system features 1,500V DC full-voltage five-level protection and an active safety solution combining AI, multi-detection, and staged fire suppression, enabling closed-loop management from early warning to fire control.

Certified by International Large-Scale Fire Test, Safety Validated

Alongside the exhibition, CSA Group presented EVE Energy with a certificate for passing a large-scale fire test on its 628Ah large-format battery and 5MWh BESS. The test strictly followed international standards including CSA/ANSI C800:25, UL 9540A, and NFPA 855, verifying the system’s fire safety and thermal runaway control under extreme fire conditions. Additionally, EVE Energy’s 261kWh outdoor integrated storage cabinet received CB, CE, and AS certifications from SGS, while the S6900 BESS obtained CB and CE certifications, providing a solid compliance foundation for further overseas market expansion.

Over 50GWh in Deals, Deepening Cooperation with Industry Leaders

During the event, EVE Energy signed strategic cooperation agreements with five leading industry players: Beijing Goldwind Zero Carbon Energy Co., Ltd., Zhejiang Jinko Energy Storage Co., Ltd., Jiangsu Linyang Energy Equipment Co., Ltd., China Energy Construction Energy Storage Technology (Wuhan) Co., Ltd., and Shanghai Ronghe Yuan Energy Storage Co., Ltd.. The partnerships focus on large-format batteries and core energy storage products, with total contracted volume exceeding 50GWh.

With its new product launch, safety certifications, and large-scale orders, EVE Energy has further demonstrated its technological expertise and market strength in the large-format battery storage segment. The company stated that it will continue to deepen its core capabilities in high-capacity energy storage and work with global partners to drive the development of the energy storage industry ecosystem.